{
    "organizations": [],
    "uuid": "33a55da079110ae45f350d78def5db0f075d2282",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acorda-announces-fda-acceptance-of/brief-acorda-announces-fda-acceptance-of-new-drug-application-for-inbrija-idUSASB0C6B3",
    "ord_in_thread": 0,
    "title": "BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Acorda Therapeutics Inc:\n* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJAâ„¢ (LEVODOPA INHALATION POWDER)\n* ACORDA THERAPEUTICS INC - UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA), FDA HAS SET A TARGET DATE OF OCTOBER 5, 2018 FOR INBRIJA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T19:13:00.000+02:00",
    "crawled": "2018-02-21T21:40:36.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "acorda",
        "therapeutic",
        "inc",
        "acorda",
        "announces",
        "fda",
        "acceptance",
        "new",
        "drug",
        "application",
        "levodopa",
        "inhalation",
        "powder",
        "acorda",
        "therapeutic",
        "inc",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "fda",
        "set",
        "target",
        "date",
        "october",
        "inbrija",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}